Christopher R Self

Title: Christopher R Self: Innovator in Peptide Research

Introduction

Christopher R Self is a notable inventor based in Piscataway, NJ (US). He has made significant contributions to the field of peptide research, particularly in the development of compounds that can bind to CD23. His work focuses on addressing inflammatory responses associated with various diseases.

Latest Patents

Christopher R Self holds a patent for "Peptides and peptidomimetics binding to CD23." This invention describes compounds that comprise new and useful peptides and peptidomimetics capable of reducing inflammatory responses linked to autoimmune diseases, chronic inflammatory diseases, allergies, and other inflammatory conditions mediated by the mammalian immune system. The patent details a CD23-binding peptide with a specific amino-acid sequence that includes various combinations of amino acids, providing a foundation for therapeutic applications.

Career Highlights

Christopher R Self is affiliated with the Université de Bordeaux, where he continues to advance his research in peptide technology. His innovative work has the potential to lead to new treatments for inflammatory conditions, showcasing his commitment to improving health outcomes.

Collaborations

Some of his notable coworkers include Mohammad Djavad Mossalayi and Philippe Vincendeau. Their collaborative efforts contribute to the ongoing research and development in the field of peptide therapeutics.

Conclusion

Christopher R Self is a pioneering inventor whose work in peptide research holds promise for addressing significant health challenges. His contributions to the field are marked by his innovative patent and collaboration with esteemed colleagues.